Coronavirus Update: Moderna’s COVID-19 Vaccine Passes First Test In Elderly Patients
Encouraging Results From Phase I Study
Executive Summary
Plus: Korea approves Celltrion antibody trial in mild patients, promising signs for Translate Bio's mRNA candidate in animal studies.
You may also be interested in...
US COVID Vaccine Early Distribution Plans Assume Emergency Use Authorization First
CDC developing vaccine distribution plans with four states and one large city that will serve as a ‘foundation’ for other jurisdictions; plans include provisions for all potential vaccines, but logistics will vary depending on product, especially given the cold chain issues associated with mRNA vaccines from Pfizer and Moderna.
Coronavirus Update: Moderna Could Have Advantage Over Pfizer’s Cold Chain
Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.
Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid
More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine.